Immix Biopharma, Inc. Common Stock (IMMX)
Immix Biopharma, Inc. (IMMX) is a biotechnology company focused on developing and commercializing innovative therapies in the field of immuno-oncology. The company's primary goal is to advance treatments that enhance the immune system's ability to target and eliminate cancer cells, with a particular emphasis on therapies that can improve patient outcomes in oncology.
Company News
Immix Biopharma's CAR-T cell therapy NXC-201 demonstrated positive clinical results in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate and a favorable safety profile.
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. The company reported a Q4 adjusted loss of 11 cents per share, a turnaround from EPS income of $1.97 per share a year ago, missing the consensus for a loss of 5 cents per share. The insurer r...
Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Find out why IMMX stock is a Buy.
Immix Biopharma, Inc. (IMMX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Hot penny stocks to watch this week. The post Penny Stocks To Buy? 4 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.